Teva signs deal for two FDA-approved biosimilars
Teva Pharmaceutical (TEVA) signed a deal with Samsung Bioepis to commercialize two FDA-approved biosimilars, ETICOVO and infliximab-abda, in the U.S. Teva will gain rights to ETICOVO at closing and infliximab-abda in Q3 2027, with the transaction expected to close by late 2026. Teva will make payments over three years and potentially additional milestone payments.
How this was made
The 30-second read
Why it matters
The deal expands Teva's immunology offerings, potentially improving revenue and market share in the biosimilar space.
Market read
A material partnership for a large-cap pharma, likely to influence TEVA's stock and the broader immunology sector.
What to watch
Milestone payments are contingent on launches; regulatory delays could limit near‑term impact.
Background
Teva's partnership with Samsung Bioepis builds on prior collaborations and aims to bring two already FDA‑approved biosimilars to market.
Ticker impact
Teva signed a deal with Samsung Bioepis to commercialize two FDA‑approved biosimilars in the U.S., expanding its immunology portfolio.
potential upside as investors price in the expanded biosimilar portfolio.
First‑report disclosure of a material partnership for a large‑cap pharma; no prior public announcement.
Market effects
May spur competitive pressure on other immunology biosimilar developers.
U.S. immunology market sees added supply, potentially affecting pricing dynamics.
Highlights growing collaboration between U.S. and Korean biotech firms.
Counterpoint
If launch timelines slip, the market could discount the deal and TEVA may face execution risk.
Key entities
- companyTeva Pharmaceutical Industries
U.S.-listed pharmaceutical company expanding its biosimilar portfolio.
- companySamsung Bioepis
Korean biotech partner providing manufacturing and regulatory oversight.
